Open Access

Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas – a single centre experience

Lucka Boltezar

Lucka Boltezar

Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Boltezar, Lucka
, 
Karlo Pintaric

Karlo Pintaric

Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Pintaric, Karlo
, 
Jože Pretnar

Jože Pretnar

Department of Hematology, University Clinical Centre LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Pretnar, Jože
, 
Maja Pohar Perme

Maja Pohar Perme

Department of Biostatistics and Medical Informatics, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Pohar Perme, Maja
 and 
Barbara Jezersek Novakovic

Barbara Jezersek Novakovic

Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Novakovic, Barbara Jezersek
  
Jun 24, 2016
Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas – a single centre experience's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Jun 24, 2016
Page range: 81 - 87
Received: Jan 06, 2016
Accepted: May 24, 2016
DOI: https://doi.org/10.1515/raon-2016-0040
Keywords
© 2017 Lucka Boltezar, Karlo Pintaric, Jože Pretnar, Maja Pohar Perme, Barbara Jezersek Novakovic
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
(A) Overall survival of follicular lymphoma (FL) patients (n = 17); (B) Overall survival of mantle cell lymphoma (MCL) patients (n = 29).
(A) Overall survival of follicular lymphoma (FL) patients (n = 17); (B) Overall survival of mantle cell lymphoma (MCL) patients (n = 29).
(A) Event-free survival of follicular lymphoma (FL) patients (n = 17); (B) event-free survival of mantle cell lymphoma (MCL) patients (n = 29).
(A) Event-free survival of follicular lymphoma (FL) patients (n = 17); (B) event-free survival of mantle cell lymphoma (MCL) patients (n = 29).

Patients’ characteristics

Follicular lymphoma group N = 17Mantle cell lymphoma group N = 29
Sex (F/M)7 (41.2%) / 10 (58.8%)6 (20.7%) / 23 (79. 3%)
Age at diagnosis in years, median FL grade I/II IIIa Pleomorphic/blastoid MCL46 (range 29–62) 13 (76.5%) 4 (23.5%) /54 (range 38–65) / 10 (34.5%)
Distribution according to FLIPI or MIPI low risk/intermediate/high risk HDT/ASCT After first line treatment* After second line treatment or later

according to national guidelines; CR = complete remission; F = female; FL = follicular lymphoma; FLIPI = follicular lymphoma international prognostic index; HDT/ASCT = high dose treatment/autologous stem cell transplantation; M = male; MCL = mantle cell lymphoma; MIPI = international prognostic index for mantle cell lymphoma; N = number; PR = partial remission

4 (23.5%) / 9 (52.9%) / 4 (23.5%) 3 (17.6%) 14 (82.4%)24 (82.8%) / 4 (13.8%) / 1 (3.4%) 24 (82.7%) 5 (17.2%)
Disease status prior HDT/ASCT CR PR Documented rituximab treatment before HDT/ ASCT5 (29.4%) 12 (70.6%) 17 (100%)13 (44.8%) 16 (55.2%) 29 (100%)
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed